Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
about
Prevention of vertical transmission of HIV-1 in resource-limited settingsThe spread, treatment, and prevention of HIV-1: evolution of a global pandemicAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionPre-exposure chemoprophylaxis for HIV: it is timeEmergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated childHIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysisOptimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settingsEmergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxisDevelopment of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, MozambiquePregnancy and virologic response to antiretroviral therapy in South AfricaBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesHIV-1 Genetic Variability and Clinical ImplicationsImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrNevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infantsComparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsMinority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Accelerated Recurrence Time Models.HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assaysIntrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.What can we do to reduce mother to child transmission of HIV?Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.Genotypic testing for human immunodeficiency virus type 1 drug resistance.The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort studyPerformance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from UgandaMinor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, MozambiqueEfficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineImmunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.Primary drug resistance in South Africa: data from 10 years of surveys.Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
P2860
Q22241479-E478BD8C-6468-40F8-9376-2E019DB5BE55Q22241890-9E13AA80-470E-4807-853F-254C0CFB377AQ24235500-D339500B-59E1-4C70-8FD8-9F38344D1221Q24243146-1575ECF1-E96D-487E-B8CA-C9823F528162Q24792802-0E48393A-4136-476D-B54B-7AE0441F53ECQ28474989-33E6830E-D3AF-4539-B4A7-9E9E86C7C478Q28477542-C27C070B-2793-4588-BDB1-317AFD9A6AF5Q28478154-7F7AE4EA-F21C-4EE3-9E53-DF8E4FB59257Q28478377-E73ECDD1-C18F-41E7-9487-0111B740BEECQ28546418-3DA4B8F7-94D8-40C5-8202-C1C07BCC3E23Q28741879-2BEC14DA-58F6-4AAA-889C-F6F4047575D5Q28775900-79C1EE62-BA78-466C-ADC4-E1E060EA9F8FQ30352010-F6A2492C-C564-40A7-B366-AF1FD6C1A31AQ33267065-52C28548-1D61-4750-B0D3-189FE9160C6AQ33396950-D4DEA39D-F988-407C-9A7D-D40CADE3AF9BQ33561750-A564FE9C-A546-468E-9E77-0413D76EA0E2Q33601530-02E5C179-0C6A-4935-91B6-837925E95098Q33605273-86487FD3-438F-44B7-88DC-AE20DBE8EAB8Q33617285-BBB1D480-24DE-4A59-A707-2043EFD63E7BQ33636945-888C7306-0A8F-43FB-A6F0-1182437CCB2FQ33686931-AA17389D-B48D-47DD-9E92-4E473C0150E3Q33722976-9EC0AC3E-29AC-4DC9-95D0-D5F96BE6EA5DQ33739249-D3F12046-75AB-42ED-B9CE-156A19C1B426Q33745946-3C209DE9-F338-4CEA-8CCC-537E0D10348AQ33749434-BF4BE813-0702-43B6-A434-115A4BD9D6A0Q33798282-5E910378-5422-46C2-85C9-436FF89F19C9Q33808840-BA85FDB2-4DC1-4390-A4AC-EEB9D01569BAQ33827841-37A2CD0E-2C04-4E99-AD67-F99B7D8A6DE9Q33906239-6A55EBC6-4D65-47CD-8F09-F16938D6944BQ33939293-FFA52124-FB7C-46E2-B44C-B2D0C69BFCE2Q33974239-1C7FA5A5-EAF3-44F4-A976-9AE657BD81A7Q34019433-5F7BA010-5E94-44CE-A2D4-4913F227ADB2Q34033166-244CB746-C5BC-4AE3-8C1C-DFF21C50482BQ34048188-3F1B50DD-8817-47A5-9AB9-25DF8F882A2CQ34071112-32E0F604-C748-46D3-9A36-33CEDEC02AC2Q34078266-C0744276-197C-4008-8C1F-9F5F7FC624F8Q34120725-36C5DC53-0198-4DE8-BAFC-A18C97FA9D14Q34129300-2D1548DE-586D-42DD-8B59-E04B2AE9B9F3Q34200009-68EBC27E-89FF-4B86-B01C-8E0C76AFFC24Q34249966-76B3610C-DCE1-4DC5-93CD-1CA6EF422EC8
P2860
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Selection and fading of resist ...... cal transmission (HIVNET 012).
@en
type
label
Selection and fading of resist ...... cal transmission (HIVNET 012).
@en
prefLabel
Selection and fading of resist ...... cal transmission (HIVNET 012).
@en
P2093
P1433
P1476
Selection and fading of resist ...... cal transmission (HIVNET 012).
@en
P2093
Cunningham S
Eshleman SH
Glenn Fowler M
Jackson JB
Mirochnick M
Mofenson LM
P304
P356
10.1097/00002030-200110190-00006
P407
P577
2001-10-01T00:00:00Z